Compare RLX Technology Inc (RLX) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
RLX Technology Inc vs Smith & Nephew plc — how do they compare? RLX Technology Inc trades at $1.74 (market cap $2.10B), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 5.3× RLX Technology Inc's market cap, and RLX Technology Inc pays the higher dividend (5.81%). Which is the better fit depends on your goals — on Pluang, investors hold RLX Technology Inc for 35 Days and Smith & Nephew plc for 121 Days on average.
| RLX | SNN | |
|---|---|---|
Market Cap | $2.10B | $11.10B |
Volume | 1,079,706 | 1,051,703 |
Sector | Consumer Staples | Health |
52-Week High | $2.57 | $37.17 |
52-Week Low | $1.68 | $26.42 |
Typical Hold Time | 35 Days | 121 Days |
Enterprise Value | $832.26M | $14.13B |
Dividend Yield | 5.81% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RLX Technology trades at $1.735, up 0.29% with bearish technical signals despite recent 52-week lows. The company shows solid fundamentals with $3.62B revenue, 21.87% net margin, and attractive valuation at P/E 15.46 and P/B 0.91. Recent earnings missed expectations but international expansion drives growth, with 70% revenue now from overseas markets. Cash flow trends improved significantly from -$99M in 2025 to $881M projected for 2026.
RLX presents a value opportunity with discounted valuation and strong international growth, though technical weakness and earnings misses warrant caution. The single analyst coverage maintains Hold rating, reflecting uncertainty amid expansion execution risks and regulatory challenges in the e-vapor industry.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
